Sponsored Content

Future focus: Our 2020 vision

Cambrex eBook: The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021, driven by positive industry trends — many of which our experts commented on in Part 1 of the Cambrex eBook. Market data shows just how...

Small Molecules: 2020 Vision

Cambrex experts have contributed more articles to our biggest eBook yet. The industry trend of outsourcing to CDMOs continues. With more services, capabilities, facilities and employees than ever before. Enjoy Part 1 of our latest Cambrex...

Digital Transformation in 2020: What Should Pharma Know?

To extract continuous value from R&D activities and ensure manufacturing quality, pharmaceutical companies are – or should be – embracing digital transformation. This business journey uses technology to turn fragmented systems into a harmonized...

A winning pediatric dosage formulation

When a global pharmaceutical company’s pediatric formulation and dosage form(s) didn’t fit the plant equipment profile used to manufacture the adult dosage form at the customer’s facility, they needed a high quality, agile CDMO with...

Cambrex eBook - Small molecules 2.0: the bigger picture

The Cambrex eBook contains 30 more thought leading articles from the world's fastest growing small molecule company. Discover the highest number of NCEs approved by the FDA.

Continuous Flow for APIs and Intermediates (Part 2)

Cambrex’s Dr. Shawn Conway, Director of Engineering, R&D, outlines how continuous flow processes simplify and break through traditional method limitations to achieve efficiencies in cost, quality and safety. Discussion includes how current...

Continuous Flow for APIs & Intermediates (Part 1)

After a brief history of the continuous flow process, Cambrex’s Jonathan Knight and Fredrik Stenberg discuss its benefits over traditional batch operations – including cost, quality and safety.

Sponsored Content

Login Form